DocMorris (DOCM) Q3 2026 TU earnings summary

Executive summary

• Q3 external revenue grew 21.5% YoY in local currency; adjusted EBITDA reached CHF 0.6 million, achieving the 2026 breakeven target ahead of schedule.

• Active customers increased by 1.5 million YoY to 13.1 million; 0.2 million were added in Q3, including above-average growth in new Rx customers.

Financial highlights

• Q3 external revenue was CHF 342.7 million, up 21.4% reported and 21.5% in local currency; revenue was CHF 327.4 million, up 22.1% and 22.2%, respectively.

• 9M external revenue rose 13.6% reported to CHF 970.6 million, or 15.5% in local currency; revenue increased 14.5% to CHF 926.6 million, or 16.4% in local currency.

• Q3 adjusted EBITDA was CHF 0.6 million, reaching targeted breakeven ahead of schedule.

Outlook and guidance

• FY 2026 external revenue growth guidance raised to 12.5–15% from 9–13%; adjusted EBITDA guidance raised to better than minus CHF 10 million from minus CHF 10 million to minus CHF 17.5 million.

• FY 2026 capital expenditure guidance remains below CHF 30 million; free cash flow breakeven target remains during 2027, with medium-term targets unchanged.